211 related articles for article (PubMed ID: 38638855)
1. Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications.
Wasik MA; Kim PM; Nejati R
Front Oncol; 2024; 14():1383741. PubMed ID: 38638855
[TBL] [Abstract][Full Text] [Related]
2. B-cell receptor signaling as a driver of lymphoma development and evolution.
Niemann CU; Wiestner A
Semin Cancer Biol; 2013 Dec; 23(6):410-21. PubMed ID: 24060900
[TBL] [Abstract][Full Text] [Related]
3. T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell.
Serwold T; Hochedlinger K; Swindle J; Hedgpeth J; Jaenisch R; Weissman IL
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18939-43. PubMed ID: 20956329
[TBL] [Abstract][Full Text] [Related]
4. [Analyses of the rearrangement of T-cell receptor- and immunoglobulin genes in the diagnosis of lymphoproliferative disorders].
Griesser DH
Veroff Pathol; 1995; 144():1-109. PubMed ID: 7856305
[TBL] [Abstract][Full Text] [Related]
5. Relationships among expression, transcription and rearrangement of T-cell receptor beta gene in T-cell lymphomas.
Kasai K; Kameya T; Ono M; Wada C; Kuwao S; Motoori T
Virchows Arch A Pathol Anat Histopathol; 1990; 417(1):57-65. PubMed ID: 2163138
[TBL] [Abstract][Full Text] [Related]
6. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Analysis of immunoglobulin, T cell receptor and bcr rearrangements in human malignant lymphoma and Hodgkin's disease.
Tesch H; May P; Krueger GR; Fischer R; Diehl V
Oncology; 1990; 47(3):215-23. PubMed ID: 2160631
[TBL] [Abstract][Full Text] [Related]
9. TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.
Whillock AL; Ybarra TK; Bishop GA
J Biol Chem; 2021; 296():100465. PubMed ID: 33639170
[TBL] [Abstract][Full Text] [Related]
10. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.
Stein H; Mason DY; Gerdes J; O'Connor N; Wainscoat J; Pallesen G; Gatter K; Falini B; Delsol G; Lemke H
Blood; 1985 Oct; 66(4):848-58. PubMed ID: 3876124
[TBL] [Abstract][Full Text] [Related]
11. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas.
Boulland ML; Kanavaros P; Wechsler J; Casiraghi O; Gaulard P
J Pathol; 1997 Dec; 183(4):432-9. PubMed ID: 9496260
[TBL] [Abstract][Full Text] [Related]
13. Caveolin-1: The Unnoticed Player in TCR and BCR Signaling.
Fiala GJ; Minguet S
Adv Immunol; 2018; 137():83-133. PubMed ID: 29455848
[TBL] [Abstract][Full Text] [Related]
14. CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas.
Emile JF; Boulland ML; Haioun C; Kanavaros P; Petrella T; Delfau-Larue MH; Bensussan A; Farcet JP; Gaulard P
Blood; 1996 Feb; 87(4):1466-73. PubMed ID: 8608237
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
16. Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL.
Eken JA; Koning MT; Kupcova K; Sepúlveda Yáñez JH; de Groen RAL; Quinten E; Janssen J; van Bergen CAM; Vermaat JSP; Cleven A; Navarrete MA; Ylstra B; de Jong D; Havranek O; Jumaa H; Veelken H
J Exp Med; 2024 May; 221(5):. PubMed ID: 38512136
[TBL] [Abstract][Full Text] [Related]
17. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
18. Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming.
Carras S; Chartoire D; Mareschal S; Heiblig M; Marçais A; Robinot R; Urb M; Pommier RM; Julia E; Chebel A; Verney A; Bertheau C; Bardel E; Fezelot C; Courtois L; Lours C; Bouska A; Sharma S; Lefebvre C; Rouault JP; Sibon D; Ferrari A; Iqbal J; de Leval L; Gaulard P; Traverse-Glehen A; Sujobert P; Blery M; Salles G; Walzer T; Bachy E; Genestier L
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34043588
[TBL] [Abstract][Full Text] [Related]
19. Malignant B cells and antigenic receptor: necessity or habit?
Ciric B; Pease LR
Leuk Lymphoma; 2002 Jul; 43(7):1383-90. PubMed ID: 12389617
[TBL] [Abstract][Full Text] [Related]
20. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
